NAMI-A

NAMI-A is a ruthenium(III) coordination compound with the formula (ImH)[trans-RuCl4(dmso-S)(Im)], where Im = imidazole. It was developed as an antimetastatic agent and is notable for its selective inhibition of metastasis formation and growth, particularly in lung metastases of various solid tumors. Unlike conventional platinum-based cytotoxic agents (such as cisplatin), NAMI-A shows minimal inhibition of primary tumor growth and limited cytotoxic activity; its primary mode of action appears related to affecting the metastatic process, possibly through interactions with cellular adhesion and migration mechanisms. Its mechanism is believed to involve protein binding and biodistribution properties unique to ruthenium complexes. NAMI-A was first introduced into clinical trials in 1999 and underwent Phase I/II evaluation for advanced non-small cell lung cancer (NSCLC), both as monotherapy and in combination with gemcitabine. While its toxicity profile is moderate (main adverse events include renal toxicity, blisters on extremities, nausea, and gastrointestinal symptoms), clinical efficacy was limited, and further development was discontinued after early phase trials did not yield satisfactory antitumor responses[1][2][6][7][8][9][11].

Brand names

NAMI-A

Other names

imidazolium-trans-tetrachloro(dimethylsulfoxide)imidazoleruthenium(III)60487Z56XWUNII-60487Z56XWUNII60487Z56XWUNII 60487Z56XW